Top
image credit: Unsplash

FDA green light for BMS, bluebird bio’s CAR-T therapy Abecma in multiple myeloma

Abecma (idecabtagene vicleucel; ide-cel) has been cleared for use in adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.

In the Phase II KarMMa trial, the overall response rate (ORR) for the efficacy evaluable population was 72% in multiple myeloma patients receiving the CAR-T therapy, with 28% of patients achieving a stringent complete response (sCR).

Read More on Pharma Times